



Protokoll

Närvarande: Leif Kari
Sören Östlund
Sofia Nyström
Fredrik Viklund
Stefan Hallström
Björn Önfelt
Theodor Staffas

Anna Delin
Anna-Karin Burström

1. Mötets öppnande

Ordförande Leif Kari förklarar mötet öppnat.

2. Anmälda förhinder

Anna Wahl har anmält förhinder.

3. Val av justeringsperson

Björn Önfelt utses till justeringsperson.

4. Fastställande av föredragningslista [bilaga 1]

Föredragningslistan fastställs utan ändringar.

5. Föregående protokoll (rådsmöte 23 januari 2018)

Protokollet från rådsmötet 23 januari 2018 läggs till handlingarna.

6. Anmälningar [bilaga 2]

Leif Kari redovisar aktuella disputationer och licentiatseminarier enligt bilaga 2.

7. Rekryteringsärenden, fakultetsförnyelse och jämställdhet

a. Rapport av pågående ärenden [bilaga 3]

Anna Delin föredrar aktuella rekryteringsärenden, befordringsärenden och docentprövningar.

b. Förlängning av affilierad fakultet i tillämpad fysik [bilaga 4]

Anna Delin föredrar ärendet.

Strategiska rådet beslutar

att tillstyrka ärendet.

8. Övriga frågor

Regeringen gör en utredning kring styrning för starka och ansvarfulla lärosäten, STRUT. En delrapport rörande resursfördelning till universitet och högskolor har nu kommit. Rådet diskuterar rapporten.

Rådet diskuterar resurssättning av jämställdhetsarbete och kompetensbaserad rekrytering av doktorander.

Diskussion kring vilka frågor som bör behandlas i rådet.

9. Mötets avslutande

Leif Kari förklarar mötet avslutat.

Vid protokollet

Anna-Karin Burström

Justeras

Leif Kari

Björn Önfelt



Föredragningslista

*= bilaga finns

1. Mötets öppnande
2. Anmälda förhinder
3. Val av justeringsperson
4. Fastställande av föredragningslista
5. Föregående protokoll (rådsmöte 23 januari 2018)
6. Anmälningar*
7. Rekryteringsärenden, fakultetsförnyelse och jämställdhet
 - a. Rapport av pågående ärenden *
 - b. Förlängning av affilierad fakultet i tillämpad fysik*
8. Diskussion kring STRUT samt resurstilldelning för jämställdhetsprojekt.
9. Övriga frågor
10. Mötets avslutande

Licentiatseminarium



24 januari - 5 mars

6

februari

[Reduction of Audible Noise of a Traction Motor at PWM Operation](#)

Farkostteknik

Plats: E2, Lindstedtsvägen 3, KTH, Stockholm

Licentiand: Hanna Amlinger, Farkost & Flyg

23

februari

[Wind turbines over a hilly terrain: performance and wake evolution](#)

Teknisk mekanik

Plats: Sal D3, Lindstedtsvägen 5, KTH, Stockholm

Licentiand: Ann Hyvärinen, Mekanik

23

februari

[Two problems in nonlinear PDEs with phase transitions](#)

Matematik

Plats: Two problems in nonlinear PDEs with phase transitions

Licentiand: Karl Jonsson, Matematik

Disputation



24 januari - 5 mars

26

januari

[Processing of self-reinforced poly\(ethylene terephthalate\) composites for automotive applicatio](#)

Farkostteknik

Plats: Kollegiesalen, Brinellvägen 8, 4tr, KTH, Stockholm

Respondent: Lars Jerpdal, Farkost och Flyg

26

januari

[Fast methods for electrostatic calculations in molecular dynamics simulations](#)

Tillämpad matematik och beräkningsmatematik - Numerisk Analys

Plats: sal F3, Lindstedtsvägen 26, KTH, Stockholm

Respondent: Davood Saffar Shamshirgar, Matematik

6

februari

[On Heavy-Haul Wheel Damages using Vehicle Dynamics Simulation](#)

Farkostteknik

Plats: Sal F3, Lindstedtsvägen 26, KTH, Stockholm

Respondent: Saeed Hossein-Nia, Farkost och Flyg

6

februari

[On Heavy-Haul Wheel Damages using Vehicle Dynamics Simulation](#)

Farkostteknik

Plats: Sal F3, Lindstedtsvägen 26, KTH, Stockholm

Respondent: Saeed Hossein-Nia, Farkost och Flyg

9

februari

[Density Functional Theory Calculations for Graphene-based Gas Sensor Technology](#)

Fysik - Material- och nanofysik

Plats: sal C (Sven-Olof Öhrvik), Kistagången 16, Electrum 1, KTH, Kista

Respondent: Karim Elgammal, Tillämpad fysik

9

februari

[Structure formation, phase transitions and drag interactions in multicomponent superconductor:](#)

Fysik - Teoretisk fysik

Plats: sal FB 42, AlbaNova Universitetscentrum, Roslagstullsbacken 21, Stockholm

Respondent: Karl Sellin, Fysik

19

februari

[Strong Cosmic Censorship and Cosmic No-Hair in spacetimes with symmetries](#)

Matematik

Plats: sal F3, Lindstedtsvägen 26, KTH, Stockholm

Respondent: Katharina Maria Radermacher, Matematik

Skola	Befattning	Ämnesområde	Diarienummer	Notering	Behöver göras
SCI	Biträdande lektor	flygteknik	S-2016-1309	Intervjumöte 7 februari. Expedierade ärendet 14 februari.	Invänta referenstagning (till Source 8/2)
SCI	Biträdande lektor	Expermentell kvantfotonik ENLIGT ANNA DELIN SKA ÄMNESOMRÅDET ÄNDRAS	S-2018-0111	FR 2018-02-07.	Rektors inrättande, AU anställningsprofil
SCI	Lektor	matematik (2st)	VL-2017-0009	Expedierat 2017-12-15	Invänta beslut från skolan. Annars är allt färdigt
SCI	Lektor	Matematisk statistik		RN 2018-03-23 intervjuer med 6 sökande	

Docentärenden

Pågående ärenden	
Ilaria Testa	hos sakkunnig
Kevin Schnell	AU 27/2
Walter Villanueva	hos sakkunnig
Ivan Stenius	hos sakkunnig
Lilian Mathiesen	Överlämnades till UF 19 feb
Martin Månsson	Väntar på skolans brev och förslag på sakkunnig
Sara Zahedi	Överlämnades till UF 19 feb
Lucie Delamotte	Väntar på skolans brev och förslag på sakkunnig

Affilieringar och befordringsärenden

Namn	Position	Ämnesområde	Dnr	Status
Nina Kirchners	Affilierad fakultet(förlängning)	Marina System	VL-2018-0023	Beslut om förlängning klart och distribuerat i februari
Mats Jonasson	Affilierad fakultet(ny)	Fordonsdynamik med särskild inriktning mot innovativa fordonskoncept	VL-2018-0007	Beslut om utnämning klart och distribuerat i februari
Martin Månsson	Befordran till lektor	Neutronspridning	VL-2017-0229	Ej komplett sakkunnigförslag i systemet
Josefin Larsson	Befordran till lektor	fysik med inriktning mot experimentell astropartikelfysik	VL-2017-0196	Inkom 31 januari 2018. AU möte 27 februari 2018
Chong Qi	Befordran till lektor	Teoretisk kärnfysik	VL-2017-0188	Inkom 31 januari 2018. AU möte 27 februari 2018
Sara Zahedi	Befordran till lektor	Numerisk analys	VL-2017-0183	Inkom 31 januari 2018. AU möte 27 februari 2018
Ivan Stenius	Befordran till lektor	Marina system	VL-2017-0147	Beslut om anställning som lektor klar. Gäller fr.o.m. 1 feb 2018.

Jonas Weissenrieder	Befordran till professor	materialfysik	VL-2018-0002	Inkom 31 januari 2018.
Philipp Schlatter	Befordran till professor	strömningsmekanik	VL-2017-0221	Inkom 31 januari 2018.
Berk Hess	Befordran till professor	biofysik	VL-2017-0210	Inkom 31 januari 2018.
Carlota Canalias	Befordran till professor	tillämpad fysik	VL-2017-0184	Inkom 31 januari 2018.
Malin Åkermo	Befordran till professor	Lättkonstruktioner	VL-2017-0037	Beslut om anställning som professor klar. Gäller fr.o.m. januari 2018
Elena Gutierrez Farewik	Befordran till professor	Biomekanik, särskilt muskelarbetets mekanik	VL-2017-0011	Beslut om anställning som professor klar. Gäller fr.o.m. januari 2018



KTH Engineering Sciences

Inst. för tillämpad fysik
Peter Unsbo

Rektor

Stockholm 2018-02-26

Förslag till förlängning av affiliering av docent Michael Uhlin till skolan för teknikvetenskap, KTH

KTH, Skolan för teknikvetenskap föreslår, med bifall från Karolinska Universitetssjukhuset, att förlänga Michael Uhlins affiliering vid KTH, Skolan för teknikvetenskap, knuten till forskargruppen i biofysik vid institutionen för tillämpad fysik.

Under våren 2014 tilldelades Björn Önfelt, verksam vid institutionen för tillämpad fysik, KTH ett större anslag från Stiftelsen för Strategisk Forskning riktat mot att utveckla encells-metoder för cellterapi. Medsökande var bl.a. docent Michael Uhlin, Områdeschef på Klinisk Immunologi och Transfusionsmedicin (KITM), Karolinska Universitetssjukhuset. Michael har en forskarbakgrund inom immunologi och har under de senaste åren byggt upp en självständig forskningslinje inom adaptiv cellterapi. Inom det fältet har man sett ett ökat behov av nya metoder för att ingående studera de celler som används vid terapi för att t.ex. förbättra val av donatorer vid stamcellstransplantation och för att hitta unika celler för cellterapi mot cancer. Ett flerårigt samarbete mellan Michael och Björn med inriktning mot att lösa just dessa frågor ligger till grund för det stora anslaget från SSF. Detta anslag har Björn och Michael nu följt upp med flera gemensamma artiklar och anslag från bl.a. Vinnova, ALF stockholm och Cancerfonden. För att kunna fortsätta att utveckla dessa synergieffekter mellan Michaels och Björns verksamheter ser vi en fördel med att försätta Michael Uhlins affiliering som fakultetsmedlem till verksamheten på KTH. I och med det kommer vi lättare kunna etablera nya biologiska metoder på KTH, bl.a. för arbete med patientmaterial från CAST. Michael kommer att bidra med sin erfarenhet från gränsöverskridande forskning mellan klinisk och basal immunologi och fungera som handledare för doktorander och postdocs. Michael kommer även kunna bidra till grundutbildningen på KTH framförallt genom att ta del i att designa och handleda examensarbeten i gränslandet mellan teknik och biologi. En affiliering ligger även i linje med KTHs strategiska mål att komma närmare kliniskt relevant forskning genom samarbete med Stockholms läns landsting.

Institutionen för tillämpad fysik ställer en arbetsplats och övrig nödvändig utrustning till förfogande för Michael Uhlin under tiden för samarbetet. Övrig finansiering kommer från Karolinska Universitetssjukhuset. Skolan och institutionen är medvetna om att arbetsmiljölagens regler gäller för affilierad fakultet vid dennes vistelse vid KTH under tiden för samarbetet.

Michael Uhlin föreslås således affilieras till KTH under ytterligare en period av 3 år till en omfattning av cirka 25%.

Med vänliga hälsningar

Peter Unsbo
Prefekt, institutionen för Tillämpad fysik, KTH

Leif Kari
Skolchef, Skolan för teknikvetenskap



KAROLINSKA

UNIVERSITETSLABORATORIET

Klinisk immunologi/Transfusionsmedicin
Karolinska Universitetssjukhuset

1(1)

2018-01-17

Maria Matl
Funktionsområdeschef

Härmed tillstyrks Michael Uhlin affiliering till KTH som fakultetsmedlem under 3 år och att han kan använda 25% av sin arbetstid till detta.

Med vänlig hälsning

Maria Matl
Klinisk immunologi och Transfusionsmedicin
Karolinska Universitetssjukhuset

Angående Affiliering till KTH, Inst. för Tillämpad fysik.

Jag har ett starkt intresse av att förlänga min anknytning till KTH, Inst. för tillämpad fysik som affilierad Fakultet. Under de 3 år som jag varit affilierad till KTH har jag lyckosamt uppnått följande vilket tror har varit till gagn för institutionen.

Jag har publicerat över 20 Artiklar som finns att hitta på pubmed/web of science. Alla som affilierad till KTH.

Jag har tillsammans med Björn Önfelt, KTH fått gemensamma anslag från bl a Cancerfonden, barncancerfonden, Vinnova och ALF Stockholm.

Tillsammans med Björn är jag dessutom bihandledare för 2 stycken av hand doktorander.

Jag har som avsikt att ägna 25 % av min tid till KTHs verksamhet inom min affiliering.

Mvh Michael Uhlin, 23 Februari 2019.

Curriculum Vitae

Personal Information

Name: **Michael Uhlin**
Birth data: **1978-01-05**
Address: **Gruvgatan 17, 79162 Falun**
Family: Married, 2 children (9 and 13 years)
Phone and email: 0046-700922324,
michael.uhlin@ki.se



Education

University Courses and degrees

2002. Master's degree in medical research with a focus on biomedicine, **Karolinska Institutet, Stockholm.**

2001: 22,5 points (ECTS) Clinical Chemistry and 7,5 points Hematology, **Dublin Institute of Technology, Ireland.**

2001: 60 points ECTS in Business and Administration, **Stockholm University.**

1999: 15 points (ECTS) in Macroeconomics: Sweden in a macroeconomic perspective. **Stockholm University**

Doctoral degree

May 2006, Ph.D. in Infection biology at MTC, Karolinska Institutet, Stockholm.

Associate Professor (docent)-level competence

March 2012. Karolinska Institutet, Associate professorship in **Immunology**, Stockholm

Administrative merits

2017-now, Head of the stem cell laboratory unit and cellular analysis and development unit, Department of Clinical Immunology and Transfusion Medicine, Karolinska University hospital.

2016-now, KI-representative at the Department of paediatric hematology clinic, Karolinska University Hospital.

2016-Now, Steering group member at the Department of Clinical Immunology and Transfusion Medicine, Karolinska University hospital.

2014 – Now. Senior Researcher (group leader), Karolinska Institutet, Stockholm

2009–now. Participant in the steering committee for research training program: Allergy, Immunology and Inflammation (All) at Karolinska Institutet.

2009–now. Board member and founder of the biotech company Desumo Technologies

2011 – May 2016, Head of Research, at Centre for allogeneic stem cell transplantation (CAST), Karolinska University Hospital, Stockholm

2009– 2016 Research and development Chairman of the Centre for allogeneic stem cell transplantation (CAST), Karolinska University Hospital.

Formal Education

2014 The course: “Utvecklande Ledarskap”, Stockholm county council, Sweden, 3 days.

2013 The course: “Miljöutbildning för Chefer”, Stockholm county council, Sweden, 1 day.

2013 The course: “Avtal och arbetsrätt”, Stockholm county council, Sweden, 1 day.

2012 The course: “Arbetsmiljöutbildning för chefer och skyddsombud”, 2 days.

2012 The course: “Future leaders”, Stockholm county council, Sweden, 3 weeks.

2011 The course: “Radical Collaboration regarding collaboration and solving conflicts”, 1 week.

2011 The course: “Att leda utan att vara Chef”, 2 days.

2009 The course: “Development of groups and leaders” (UGL), leadership course owned by The Swedish military, 1 week.

2009 The course given by Karolinska Institutet, titled “Supervision of postgraduate students”.

Clinical Merits

2016-Now. Certified Jacie Inspector for Cell processing units in EBMT (EU) associated countries.

2017-Now. Internally appointed **Qualified Person (QP)** for Advanced therapeutical Medicinal products (ATMP) at Department of Clinical Immunology and Transfusion medicine, Karolinska University Hospital, Stockholm

2016 – 2017. Business Developer, at Department of Clinical Immunology and Transfusion medicine, Karolinska University Hospital, Stockholm

2011-now. Quality Manager in the clean room laboratory at the Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital

2010–now. Technical Manager at Stem Cell Laboratory, Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital

2013-2016. Several courses in Good Manufacturing Practice (GMP) and clean room techniques.

2010-Now. Author of Several (>30) clinical Standard operating procedures (SOPs) and validation reports regarding work in clean room environment and apheresis.

2015-2016. Study-responsible at the stem cell laboratory and Centre for Apheresis and stem cell handling (CASH) at the Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital.

Scientific Merits

Positions

2016 – Now. Senior Researcher (group leader), Department of Clintec, Karolinska Institutet, Stockholm

2014 – 2016. Senior Researcher (group leader), Department of Oncology and pathology, Karolinska Institutet, Stockholm

2015- Now. Affiliated Faculty, SciLife, Royal Technology High school, Department of Applied Physics

2008 – 2009 Postdoctoral fellowship with Prof. Klas Kärre, Microbiology and tumour biology Centre (MTC), Karolinska institutet.

Sep 2008 – Dec 2008 Postdoctoral fellow with Prof Victor Levitsky. **Johns Hopkins School of Medicine**, Baltimore, USA.

2006 – 2007, Postdoctoral fellowship with Prof Jonas Mattsson, Centre for allogeneic stem cell transplantation (CAST), Karolinska University Hospital.

Research grants obtained in open competition

As principal applicant

2017-2019 Vinnova	4 800 000 S.kr
2017-2018 J&J collaboration	1 800 000 S.kr
2017-2019 ALF Stockholm	2 300 000 S.kr
2017-2018 ALF HMT Stockholm	1 300 000 S.kr
2017-2018 Barncancerfonden	800 000 S.kr
2016 Kliniknära forskning	100 000 S.kr
2016 ALF HMT Stockholm	800 000 S.kr
2016 ALF Stockholm	423 000 S.kr
2016-2018 Radiumhemmet	900 000 S.kr
2015 Läkarsällskapet	450 000 S.kr
2015-2018 Vetenskapsrådet	4 000 000 S.kr
2015-2016 Barncancerfonden	500 000 s.kr
2015 ALF Stockholm	400 000 S.kr
2014 Läkarsällskapet	400 000 s.kr
2014 Clas Groschinskys minnesfond	150 000 s.kr
2014-2015 Radiumhemmet	500 000 S.kr
2013-2014 Roche RPF	3 000 000 S.kr
2013-2014 Barncancerfonden	600 000 S.kr
2012-2014 Vetenskapsrådet	3 000 000 S.kr
2010–2014 Stockholms Läns landsting	2 000 000 S.kr
2010–2012 SSMF researcher position:	2 382 000 S.kr
2009 Klas Groschinskys Minnesfond	100 000 S.kr
2009 Karolinskas Forskningsfonder	23 100 S.kr

2009 Socialstyrelsen	110 000 S.kr
2008–2009 David och Astrid Hagelens Stiftelse	400 000 S.kr
2008 Socialstyrelsen	90 000 S.kr
2007–2008 SSMF Post Doc Position and grant	620 000 S.kr

As co-applicant

2016-2018 Barncancerfonden Impl.Bidrag	1 500 000 S.kr
2014-2019 SSF (Together with B.Önfelt)	32 000 000 S.kr
2012-2015 Barncancerfonden	1 500 000 S.kr
2015 Barncancerfonden Impl.Bidrag	400 000 S.kr
2014-2016 Cancerfonden	1 500 000 S.kr
2013-2014 ALF Stockholm	1 000 000 S.kr

Current scientific collaborations

Victor Levitsky, MD, PhD, Tumor Immunology Leader. Roche Pharmaceutical Research and Early Development, Zurich

Jap Jaan Zwaginga, Professor in transfusion medicine. Leiden University Hospital

Klas Kärre, Professor, MTC, Karolinska Institutet, Stockholm

Lars Henningsohn Associate Professor and **Ove Gustavsson** Associate Professor, Dept. of Urology, Karolinska University Hospital, Huddinge.

Lars Egevad, Professor, Karolinska Institutet, Dept of Oncology and Pathology

Björn Önfelt, Professor, KTH Cellular Physics.

Hans Hägglund, Ass. Prof, Uppsala akademiska Sjukhus

Helen Kaipe, Ass. Prof. Dept. Lab medicine, Clinical Immunology, Karolinska institutet, Huddinge,

Mats Brune, Professor, Sahlgrenska university hospital, Göteborg.

Alfred Zippelius, Professor, Translational Oncology, Medical Oncology, Universität Hospital Basel

Jelena Levitskaya, Professor, Johns Hopkins medical University, US.

Elena sandalova, Ass. Prof. **Danone Research Centre (Lab), Biopolis, Singapore**

Karl-Johan Malmberg, Prof. Oslo University Hospital, Norway

Darius Sairafi, MD, PhD, Södersjukhuset, Dept of Dermatology.

Invitations to international scientific congresses as speaker or chair

3rd Stem cells conference. New frontiers in Stem cell Basic research, (19-21 Sep 2016), Riyadh, Saudiarabia.

Shandong University-KI Joint symposium (31 March-1 April), Jinan, China.

3rd EurocanPlatform Summer School on Translational Cancer Research (12-16 Oct 2016), Faros, Portugal.

20th EHA Congress in Vienna (12-14 June 2015), Vienna, Switzerland

King Abdullah International Medical Research Center (KAIMRC) Annual Scientific Forum, 8-9 Sep 2014, Jeddah, Saudia Arabia

28th European Immunogenetics and Histocompatibility Conference, EFI 2014, June 25-28, 2014 in Stockholm, Sweden

39th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT)

Location: London, ENGLAND Date: APR 07-10, 2013

BMT Tandem Meeting Location: San Diego, CA Date: FEB 01-05, 2012

35th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation Location: Goteborg, SWEDEN Date: MAR 29-APR 01, 2009

Evaluation of others' work

Invited reviewer for scientific journals

Bone Marrow Transplantation (n=9), Stem cells and Development (n=3), Cancer Immunology and Immunotherapy (n=1), Blood (n=1), J of Immunotherapy (n=2), Paediatrics Transplantation (n=3), Scandinavian J of Immunology (n=10), Annals for transplantation (n=2), Hematologica (N=3), Andrology (N=1), Urology (n=1), Placenta (n=1).

Member of thesis committee.

6 times at Karolinska Institutet, 1 time at Uppsala University and 1 time Gothenburg University.

Reviewer of external grants.

External reviewer of grants for Danish and dutch cancer societies and French "Institut National Du Cancer".

Bibliometric results: H-factor, number of total citations, total number of publications

H-Factor: **14**. Total number of citations: **763**. Total number of publications: **70** peer-reviewed articles.

Editorial Assignments:

Associate Editor **Frontiers in Immunology (2017-)** , Guest editor **Stem cells International (2017)**, Guest editor **Journal Immunology Research (2017)**.

Educational merits

Research supervision/ Education

Present

- Sara Thunberg, **Postdoctoral fellow** (2013-now), Main Supervisor
- Darius Sairafi, **Postdoctoral fellow** (2015-now), Main Supervisor
- Emelie Rådestad, PhD student, May 2015- Main Supervisor
- Ahmed Gaballa, PhD student, Oct 2015-Main Supervisor
- Tengyu Wang, PhD Student, May 2016-Main Supervisor
- Linda Larsson, PhD Student, April 2017-Main Supervisor

- Additional 4 Phd students as Co-supervisor

Earlier

- Arwen Stikvoort, PhD Student, (2012-2017), **Main Supervisor**
- Emma Watz, PhD Student 2011-2015), **Main Supervisor**
- Jens Gertow, PhD student (2008-2013) , **Main Supervisor**
- Eva Allerbring, PhD student (2009-2014), Co-supervisor
- Darius Sairafi, PhD student (2007-2013), Co-supervisor

- Adil Duru, PhD student (2009-2013), Co-supervisor
- Mantas Okas, PhD student, (2006-2010), Co-supervisor
- Sofia Berglund, PhD student (2009-2014), Co-supervisor
- Melissa Norström, **Post doc** (2013-2014), **Main supervisor**

Organizer of courses for PhD students:

2010–2014. Organizer of the PhD course “Antigen presentation and T cell activation” at Karolinska Institutet, within the All programme.

2007–2009. Organizer of the PhD course “Antigen presentation pathways and immune evasion” at Karolinska Institutet, Infection biology programme.

Teaching experience – Undergraduate and Postgraduate

Over the past 5 years I have 300 hours of teaching hours in basic education for students at Karolinska Institutet (medicine, biomedicine Bachelor and Masters programme, Dentists and laboratory technicians) in Immunology and infection biology.

More than 100 hours in courses at Karolinska Institutet for PhD students in the last 5 years.

Additional merits

Awards and honours

May 2013 Karolina Prize for "Exemplary clinical research", Karolinska University Hospital, Stockholm County Council

Aug 2015 “Best Translational research application”, Svenska läkarsällskapet

Scientific meeting and congresses

2016 Co-organizer Vänadsområdsgruppen (VOG) för stamceller I Sveriges möte i Stockholm

2011-2017 Organizer of the yearly research Symposium of Centre for allogeneic Stem cell Transplantation (CAST), Karolinska University Hospital.

2014-2015 Organizer of weekly seminar research series of Centre for allogeneic Stem cell Transplantation (CAST), Karolinska University Hospital.

Patents

US patent. US 61/280,809. System and method for detecting and quantifying active T cells or NK cells. **Uhlen M, Önfelt B, Kärre K.**

US and european patent, 61/938,791. ANTIBODIES FOR USE PRIOR TO STEM CELL TRANSPLANTATION OR RETRANSPLANTATION. **Uhlen M, Mattsson J.**

Publicationlist

Ph.D. Michael Uhlin (19780105-0357)

Gruvgatan 17

791 62 Falun

Tel (home) +46 (0) 23 22307

Tel (work) +46 (0) 8 58586319

E-mail: Michael.uhlin@ki.se

Bibliometric results:

H-Factor: **15**.

Total number of citations: **765**.

Total number of publications: **70**

1. Original articles

1. Expansion of gammadelta T cells from cord blood: a therapeutical possibility

Berglund S, Gaballa A, Sawaisorn P, Sundberg B, **Uhlin M**

Stem cells International. 2018 Jan [IN PRESS]

2. Change of apheresis device decreased the incidence of severe acute graft-versus-host disease among patients after allogeneic stem cell transplantation with sibling donors

Wang T, Remberger M, Axdorph-Nygell U, Sundin M, Björklund A, Mattsson J, **Uhlin M***, Watz E* (shared last author)

Transfusion. 2018 Jan [IN PRESS]

3. CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN- γ Production Profile.

Magalhaes I, Kalland I, Kochenderfer JN, Österborg A, **Uhlin M**, Mattsson J.

J Immunother. 2018 Jan 8.

4. Risk Factors for Severe Acute Graft-versus-Host Disease in Donor Graft Composition.

Stikvoort A, Gaballa A, Solders M, Nederlof I, Önfelt B, Sundberg B, Remberger M, Sundin M, Mattsson J, **Uhlin M**.

Biol Blood Marrow Transplant. 2017 Nov 29.

5. Assessment of TREC, KREC and telomere length in long-term survivors after allogeneic HSCT: the role of GvHD and graft source and evidence for telomere homeostasis in young recipients.

Gaballa A, Norberg A, Stikvoort A, Mattsson J, Sundberg B, Uzunel M, Remberger M, **Uhlin M**.

Bone Marrow Transplant. 2018 Jan;53(1):69-77.

6. Late presenting atypical severe combined immunodeficiency (SCID) associated with a novel missense mutation in DCLRE1C.

Sundin M, **Uhlin M**, Gaballa A, Ramme K, Kolios AG, Marits P, Nilsson J.
Pediatr Allergy Immunol. 2017 Oct 5.

7. Characterization of infiltrating lymphocytes in human benign and malignant prostate tissue.

Rådestad E, Egevad L, Jorns C, Mattsson J, Sundberg B, Nava S, Ericzon BG, Henningsohn L, Levitsky V, **Uhlin M**.
Oncotarget. 2017 Jul 24

8. Combining Flow and Mass Cytometry in the Search for Biomarkers in Chronic Graft-versus-Host Disease.

Stikvoort A, Chen Y, Rådestad E, Törlén J, Lakshmikanth T, Björklund A, Mikes J, Achour A, Gertow J, Sundberg B, Remberger M, Sundin M, Mattsson J, Brodin P, **Uhlin M**.
Front Immunol. 2017 Jun 19;8:717

9. No effect of HLA-C mismatch after allogeneic hematopoietic stem cell transplantation with unrelated donors and T-cell depletion in patients with hematological malignancies.

Magalhaes I, **Uhlin M**, Schaffer M, Sundin M, Hauzenberger D, Remberger M, Mattsson J.
Clin Transplant. 2017 Aug;31(8)

10. Functionality testing of stem cell grafts to predict infectious complications after allogeneic hematopoietic stem cell transplantation.

Nilsson J, Granrot I, Mattsson J, Omazic B, **Uhlin M**, Thunberg S.
Vox Sang. 2017 Jul;112(5):459-468.

11. Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.

Herold N, Rudd SG, Ljungblad L, Sanjiv K, Myrberg IH, Paulin CB, Heshmati Y, Hagenkort A, Kutzner J, Page BD, Calderón-Montaña JM, Loseva O, Jemth AS, Bulli L, Axelsson H, Tesi B, Valerie NC, Höglund A, Bladh J, Wiita E, Sundin M, **Uhlin M**, Rassidakis G, Heyman M, Tamm KP, Warpman-Berglund U, Walfridsson J, Lehmann S, Grandér D, Lundbäck T, Kogner P, Henter JI, Helleday T, Schaller T.
Nat Med. 2017 Feb;23(2):256-263

12. Donor Cell Composition and Reactivity Predict Risk of Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.

Sairafi D, Stikvoort A, Gertow J, Mattsson J, **Uhlin M**.
J Immunol Res. 2016;2016:5601204.

13. High incidence of severe chronic GvHD after HSCT with sibling donors. A single center analysis.
Remberger M, Afram G, Sundin M, **Uhlin M**, LeBlanc K, Björklund A, Mattsson J, Ljungman P.
Bone Marrow Transplant. 2016 Nov;51(11):1518-1521
14. Long-Term Stable Mixed Chimerism after Hematopoietic Stem Cell Transplantation in Patients with Non-Malignant Disease, Shall We Be Tolerant?
Stikvoort A, Sundin M, Uzunel M, Gertow J, Sundberg B, Schaffer M, Mattsson J, **Uhlin M**.
PLoS One. 2016 May 6;11(5):e0154737
15. Microchip Screening Platform for Single Cell Assessment of NK Cell Cytotoxicity.
Guldevall K, Brandt L, Forslund E, Olofsson K, Frisk TW, Olofsson PE, Gustafsson K, Manneberg O, Vanherberghen B, Brismar H, Kärre K, **Uhlin M**, Önfelt B.
Front Immunol. 2016 Apr 5;7:119
16. Progression of benign prostatic hyperplasia is associated with pro-inflammatory mediators and chronic activation of prostate-infiltrating lymphocytes.
Norström MM, Rådestad E, Sundberg B, Mattsson J, Henningsohn L, Levitsky V, **Uhlin M**.
Oncotarget. 2016 Apr 26;7(17):23581-93
17. Single-Cell Characterization of in vitro Migration and Interaction Dynamics of T Cells Expanded with IL-2 and IL-7.
Tauriainen J, Gustafsson K, Göthlin M, Gertow J, Buggert M, Frisk TW, Karlsson AC, **Uhlin M**, Önfelt B.
Front Immunol. 2015 Apr 28;6:196
18. Expanded umbilical cord blood T cells used as donor lymphocyte infusions after umbilical cord blood transplantation.
Berglund S, Gertow J, **Uhlin M**, Mattsson J.
Cytotherapy. 2014 Nov;16(11):1528-36
19. Effect of Total Nucleated and CD34(+) Cell Dose on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation.
Remberger M, Törlén J, Ringdén O, Engström M, Watz E, **Uhlin M**, Mattsson J.
Biol Blood Marrow Transplant. 2015 May;21(5):889-93
20. Quality of the hematopoietic stem cell graft affects the clinical outcome of allogeneic stem cell transplantation.
Watz E, Remberger M, Ringden O, Ljungman P, Sundin M, Mattsson J, **Uhlin M**.
Transfusion. 2015 May 13

21. Alpha/beta T-cell depleted grafts as an immunological booster to treat graft failure after hematopoietic stem cell transplantation with HLA-matched related and unrelated donors
Rådestad E, Wikell H, Engström M, Watz E, Thunberg S, Sundberg B, Uzunel M, Mattsson J, **Uhlin M**.
J Immunol Res. 2014;2014:578741
22. Expanded umbilical cord blood T cells used as donor lymphocyte infusions after umbilical cord blood transplantation.
Berglund S, Gertow J, **Uhlin M**, Mattsson J.
Cytotherapy. 2014 Nov;16(11):1528-36.
23. Novel method to characterize immune cells from human prostate tissue.
Norström MM, Rådestad E, Stikvoort A, Egevad L, Bergqvist M, Henningsohn L, Mattsson J, Levitsky V, **Uhlin M**.
Prostate. 2014 Oct;74(14):1391-9.
24. T-cell receptor excision circles levels after allogeneic stem cell transplantation are predictive of relapse in patients with AML and MDS.
Uzunel M, Sairafi D, Remberger M, Mattsson J, **Uhlin M**.
Stem Cells Dev. 2014 Mar 11. [Epub ahead of print]
25. Splenectomy prior to allogeneic hematopoietic SCT increases the risk of post-transplant lymphoproliferative disease.
Uhlin M, Norström MM, Mattsson J, Remberger M.
Bone Marrow Transplant. 2014 Mar;49(3):463-4
26. Analysis of donor and recipient ABO incompatibility and antibody-associated complications after allogeneic stem cell transplantation with reduced-intensity conditioning.
Watz E, Remberger M, Ringden O, Lundahl J, Ljungman P, Mattsson J, Wikman A, **Uhlin M**.
Biol Blood Marrow Transplant. 2014 Feb;20(2):264-71.
27. *Cord blood T-cells cultured with IL-7 in addition to IL-2 exhibit a higher degree of polyfunctionality and superior proliferation potential
Berglund S, Gertow J, Magalhaes I, Mattsson J, **Uhlin M**
Journal of Immunotherapy, 2013 Oct;36(8):432-41
28. *Risk factors for Epstein Barr virus related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation
Uhlin M, Wikell H, Sundin M, Blennow O, Maeurer M, Ringden O, Winiarski J, Ljungman P, Remberger M, Mattsson J
Haematologica, 2014 Feb;99(2):346-52.

29. Cord blood graft composition impacts the clinical outcome of allogeneic stem cell transplantation
Wikell H, Ponandai-Srinivasan S, Mattsson J, Gertow J, **M. Uhlin M**
Transplant Infectious Disease. 2014 Jan 24
30. A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors.
Remberger M, Ringdén O, Hägglund H, Svahn BM, Ljungman P, **Uhlin M**, Mattsson J.
Clin Transplant. 2013 Jul;27(4)
31. Chimerism patterns of long-term stable mixed chimeras posthematopoietic stem cell transplantation in patients with nonmalignant diseases: follow-up of long-term stable mixed chimerism patients.
Stikvoort A, Gertow J, Sundin M, Remberger M, Mattsson J, **Uhlin M**.
Biol Blood Marrow Transplant. 2013 May;19(5):838-44
32. Chimerism development and clinical outcome after umbilical cord blood transplantation.
S. Berglund, K Le Blanc, M. Remberger, J. Gertow, Svenberg P, Winiarski J, Ljungman P, Ringden O , **M. Uhlin***, J. Mattsson*
*Shared last authorship
Transplantation. Nov 2012.27;94(10):1066-74
33. Sirolimus and tacrolimus as immune prophylaxis compared to cyclosporine with or without methotrexate in patients undergoing allogeneic haematopoietic stem cell transplantation for non-malignant disorders.
Ringdén O, Remberger M, Dahllöf G, Garming-Legert K, Karlsson H, Svenberg P, **Uhlin M**, Uzunel M, Mattsson J.
Eur J Haematol. 2011 Dec;87(6):503-9. d
34. Unexpected T-cell recognition of an altered peptide ligand is driven by reversed thermodynamics.
Allerbring EB, Duru AD, Uchtenhagen H, Madhurantakam C, Tomek MB, Grimm S, Mazumdar PA, Friemann R, **Uhlin M**, Sandalova T, Nygren PA, Achour A.
Eur J Immunol. 2012 Jul 26. doi: 10.1002/eji.201242588. [Epub ahead of print]
35. *Rapid salvage treatment with virus-specific T cells for therapy-resistant disease.
Uhlin M, Gertow J, Uzunel M, Okas M, Berglund S, Watz E, Brune M, Ljungman P, Maeurer M, Mattsson J.
Clin Infect Dis. 2012 Oct;55(8):1064-73. Epub 2012 Jul 17.
36. Effects of different serum-levels of ATG after unrelated donor umbilical cord blood transplantation.
Remberger M, Persson M, Mattsson J, Gustafsson B, **Uhlin M**.
Transpl Immunol. 2012 Aug;27(1):59-62. Epub 2012 Jun 15.

37. Expansion of T-cells from the cord blood graft as a predictive tool for complications and outcome of cord blood transplantation.
Gertow J, Berglund S, Okas M, Kärre K, Remberger M, Mattsson J, **Uhlin M**.
Clin Immunol. 2012 May;143(2):134-44. Epub 2012 Feb 10.
38. Thymic function after allogeneic stem cell transplantation is dependent on graft source and predictive of long term survival.
Sairafi D, Mattsson J, **Uhlin M**, Uzunel M.
Clin Immunol. 2012 Mar;142(3):343-50. Epub 2011 Dec 16.
39. Mesenchymal stem cells inhibit thymic reconstitution after allogeneic cord blood transplantation.
Uhlin M, Sairafi D, Berglund S, Thunberg S, Gertow J, Ringden O, Uzunel M, Remberger M, Mattsson J.
Stem Cells Dev. 2012 Jun 10;21(9):1409-17. Epub 2011 Oct 12.
40. Immune modulation to prevent antibody-mediated rejection after allogeneic hematopoietic stem cell transplantation.
Nordlander A, **Uhlin M**, Ringdén O, Kumlien G, Hauzenberger D, Mattsson J.
Transpl Immunol. 2011 Sep;25(2-3)
41. Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study.
Remberger M, Ackefors M, Berglund S, Blennow O, Dahllöf G, Svahn BM, Svenberg P, Swartling L, Szakos A, **Uhlin M**, Uzunel M, Watz E, Wernerson A, Wikman A, Wikström AC, Winiarski J, Ringdén O.
Biol Blood Marrow Transplant. 2011 Nov;17(11):1688-97. Epub 2011 May 11.
42. Characterization of long-term mixed donor-donor chimerism after double cord blood transplantation.
Gertow J, Berglund S, Okas M, Uzunel M, Berg L, Kärre K, Mattsson J, **Uhlin M**.
Clin Exp Immunol. 2010 Oct;162(1):146-55. doi: 10.1111/j.1365-2249.2010.04212.x.
Epub 2010 Aug 20.
43. Leukemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions.
Sairafi D, Remberger M, **Uhlin M**, Ljungman P, Ringdén O, Mattsson J.
Biol Blood Marrow Transplant. 2010 Dec;16(12):1728-37. Epub 2010 Jun 10.
44. *Clinical expansion of cord blood-derived T cells for use as donor lymphocyte infusion after cord blood transplantation.
Okas M, Gertow J, Uzunel M, Karlsson H, Westgren M, Kärre K, Ringden O, Mattsson J, **Uhlin M**.
J Immunother. 2010 Jan;33(1):96-105.

45. *A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation.
Uhlin M, Okas M, Gertow J, Uzunel M, Brismar TB, Mattsson J.
Cancer Immunol Immunother. 2010 Mar;59(3):473-7. Epub 2009 Nov 12.
46. Stable mixed donor-donor chimerism after double cord blood transplantation.
Berglund S, Okas M, Gertow J, **Uhlin M**, Mattsson J.
Int J Hematol. 2009 Nov;90(4):526-31. Epub 2009 Aug 22.
47. Cytotoxic crossmatch analysis before allo-SCT is a poor diagnostic tool for prediction of rejection.
Mattsson J, Nordlander A, Remberger M, **Uhlin M**, Holgersson J, Ringdén O, Hauzenberger D.
Bone Marrow Transplant. 2010 Feb;45(2):235-8. Epub 2009 Jun 29.
48. Increased frequency and responsiveness of PSA-specific T cells after allogeneic hematopoietic stem-cell transplantation.
Uhlin M, Okas M, Karlsson H, Gertow J, Henningsohn L, Ringdén O, Kärre K, Levitsky V, Mattsson J.
Transplantation. 2009 Feb 27;87(4):467-72.
49. Unrelated cord blood and mismatched unrelated volunteer donor transplants, two alternatives in patients who lack an HLA-identical donor.
Ringdén O, Okas M, **Uhlin M**, Uzunel M, Remberger M, Mattsson J.
Bone Marrow Transplant. 2008 Nov;42(10):643-8. Epub 2008 Sep 1.
50. Effect of frequently used chemotherapeutic drugs on cytotoxic activity of human cytotoxic T-lymphocytes.
Markasz L, Skribek H, **Uhlin M**, Otvos R, Flaberg E, Eksborg S, Olah E, Stuber G, Szekely L.
J Immunother. 2008 Apr;31(3):283-93.
51. Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes.
Rasmuson I, **Uhlin M**, Le Blanc K, Levitsky V.
J Leukoc Biol. 2007 Oct;82(4):887-93. Epub 2007 Jul 3.
52. Help signals provided by lymphokines modulate the activation and apoptotic programs induced by partially agonistic peptides in specific cytotoxic T lymphocytes.
Uhlin M, Sandalova E, Masucci MG, Levitsky V.
Eur J Immunol. 2005 Oct;35(10):2929-39.
53. Regulation of lck degradation and refractory state in CD8+ cytotoxic T lymphocytes.
Uhlin M, Masucci MG, Levitsky V.

Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9264-9. Epub 2005 Jun 15.

54. Pharmacological disintegration of lipid rafts decreases specific tetramer binding and disrupts the CD3 complex and CD8 heterodimer in human cytotoxic T lymphocytes.

Uhlin M, Masucci MG, Levitsky V.
Scand J Immunol. 2003 Feb;57(2):99-106.

55. Tetramer binding and secretion of interferon-gamma in response to antigenic stimulation are compatible with a range of affinities of MHC:TCR interaction and distinct programs of cytotoxic T-lymphocyte activation.

Wei CH, **Uhlin M**, Masucci MG, Levitsky V.
Hum Immunol. 2002 Oct;63(10):821-33.

2. Conference contributions

1. Risk factors for relapse in acute leukaemia after allogeneic stem cell transplantation. A single centre experience

Conference: 39th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT) Location: London, ENGLAND Date: APR 07-10, 2013

2. Varicella zoster virus disease after allogeneic haematopoietic stem cell transplantation. Incidence, risk factors and complications

Conference: 39th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT) Location: London, ENGLAND Date: APR 07-10, 2013

3. TREC after allogeneic stem cell transplantation as a predictive marker for relapse after AML and MDS/MPS

Conference: 39th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT) Location: London, ENGLAND Date: APR 07-10, 2013

4. Antibody-mediated complications as a risk factor after allogeneic stem cell transplantation

Conference: 39th Annual Meeting of the European-Group-for-Blood-and-Marrow

Transplantation (EBMT) Location: London, ENGLAND Date: APR 07-10, 2013

5. Donor cell composition and reactivity can predict risk of acute graft-versus-host disease

Conference: European Congress of Immunology Location: Glasgow, SCOTLAND Date: SEP 05-08, 2012

6. Thymic reconstitution, chimerism development and survival after cord blood transplantation

Conference: 38th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT) Location: Geneva, SWITZERLAND Date: APR 01-04, 2012

7. THYMIC FUNCTION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IS DEPENDENT ON GRAFT SOURCE AND PREDICTIVE OF LONG TERM SURVIVAL

Conference: BMT Tandem Meeting Location: San Diego, CA Date: FEB 01-05, 2012

8. Cellular, gene therapies and Cytokines

Conference: 37th European Group for Bone and Marrow Transplantation/27th Meeting of the EBMT Nurses Group/10th Meeting of the EBMT Management Group Location: Paris, FRANCE Date: APR 03-06, 2011

9. A NOVEL HAPLO-IDENTICAL ADOPTIVE CTL THERAPY AS TREATMENT FOR EBV-ASSOCIATED LYMPHOMA AFTER STEM CELL TRANSPLANTATION

February 2010: 14th Bone marrow and Stem cell transplantation Tandem meetings (Orlando, USA):

10. Induction of prostate-specific T-cells and graft-versus-tumour effect in patients with advanced prostate cancer after allogeneic stem cell transplantation

Conference: 36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting Location: Vienna, AUSTRIA Date: MAR 21-24, 2010

11. Leukaemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions

Conference: 36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting Location: Vienna, AUSTRIA Date: MAR 21-24, 2010

12. Stable mixed donor-donor chimerism after double cord blood transplantation

Conference: 35th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation Location: Goteborg, SWEDEN Date: MAR 29-APR 01, 2009

TREATMENT OF THREATENING REJECTION AFTER UMBILICAL CORD BLOOD TRANSPLANTATION WITH EX VIVO EXPANDED CB DERIVED T CELLS

Conference: Tandem Meeting on Biology of Blood and Marrow Transplantation
Location: Tampa, FL Date: FEB 11-15, 2009

13. CLINICAL ISOLATION AND EX VIVO CULTURING OF CORD BLOOD-DERIVED T CELLS FOR DONOR LYMPHOCYTE INFUSION .

Conference: Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation Location: San Diego, CA Date: FEB 13-17, 2008

14. Induction of a prostate specific T cell response after allogeneic bone marrow transplantation.”

February 2008: American Society for Blood and Marrow Transplantation (San Diego, USA) “

15. Clinical isolation and ex vivo culturing of Cord blood-derived T cells for Donor lymphocyte infusion.

October 2007: ESH - EBMT - UT MD ANDERSON CANCER CENTER - EUROCORD - NETCORD Conference: BIOLOGY AND CLINICAL APPLICATIONS OF CORD BLOOD CELLS (Paris, *France*) ”

16. Regulation of lck degradation and refractory state in CD8+ cytotoxic T-lymphocytes

August 2004: 12th Int. Congress of Immunology and 4th Annual Conference of Focis. (Montreal, *Canada*)”

3. Review articles and editorial letters

1. Therapeutic Use of Extra-Embryonic-derived Tissues

Uhlin M, Abumaree M, and Abdelalim E
Stem cells Int. 2018 [IN PRESS]

2. Lymphocytes in Placental Tissues: Immune Regulation and Translational Possibilities for Immunotherapy.

Erkers T, Stikvoort A, **Uhlin M**.
Stem Cells Int. 2017;2017:5738371. Epub 2017 Nov 19. Review.

3. Sometimes less might be more, or at least equal.

Uhlin M.
Blood. 2017 Aug 3;130(5):565-566.

4. Advances in umbilical cord blood cell therapy: the present and the future.

Berglund S, Magalhaes I, Gaballa A, Vanherberghen B, **Uhlin M**.
Expert Opin Biol Ther. 2017 Jun;17(6):691-699.

5. T Cell Receptor Excision Circle (TREC) Monitoring after Allogeneic Stem Cell Transplantation; a Predictive Marker for Complications and Clinical Outcome.
Gaballa A, Sundin M, Stikvoort A, Abumaree M, Uzunel M, Sairafi D, **Uhlin M**.
Int J Mol Sci. 2016 Oct 11;17(10). pii: E1705. Review.
6. Systems level immune response analysis and personalized medicine.
Brodin P, Valentini D, **Uhlin M**, Mattsson J, Zumla A, Maeurer MJ.
Expert Rev Clin Immunol. 2013 Apr;9(4):307-17
7. Chimerism and use of mesenchymal stem cells in umbilical cord blood transplantation.
Berglund S, **Uhlin M**, Mattsson J.
Chimerism. 2013 Jan 1;4(1).
8. Adjunct immunotherapies for tuberculosis.
Uhlin M, Andersson J, Zumla A, Maeurer M.
J Infect Dis. 2012 May 15;205 Suppl 2:S325-34. Epub 2012 Mar 29. Review.
9. Update on viral infections in lung transplantation.
Uhlin M, Mattsson J, Maeurer M.
Curr Opin Pulm Med. 2012 May;18(3):264-70.
10. Mixed chimerism after allogeneic stem cell transplantation – Focus on double cord blood transplantation
Gertow Jens, Stikvoort Arwen, Watz Emma, Mattsson Jonas and **Uhlin Michael**
J. of Blood disorders and transfusion. 2012. S1
11. Stable mixed double donor chimerism: Absence of war doesn't necessarily mean peace.
Gertow J, Mattsson J J, **Uhlin M**.
Chimerism. 2010 Oct;1(2):64-65.
12. In vitro or in vivo expansion before adoptive T-cell therapy?
Uhlin M, Mattsson J.
Immunotherapy. 2011 Feb;3(2):131-3. No abstract available.
13. The allogeneic graft-versus-cancer effect.
Ringdén O, Karlsson H, Olsson R, Omazic B, **Uhlin M**.
Br J Haematol. 2009 Dec;147(5):614-33. Epub 2009 Sep 4. Review.
14. Is the activity of partially agonistic MHC:peptide ligands dependent on the quality of immunological help?
Uhlin M, Masucci M, Levitsky V.
Scand J Immunol. 2006 Dec;64(6):581-7. Review.

4. Popular science.

Invited Editorial: The Best Strategy for Adoptive T Cell Transfer

Uhlin M

Proimmune ®, 2013